E.U. panel recommends Inlyta for adults with kidney cancer

E.U. regulators have recommended Pfizer's kidney cancer drug Inlyta be approved for use in patients who don't respond to other medications. Pfizer ($PFE) said the panel recommended approving the drug for use only in adults, reports CBS News. The FDA, in January, approved the twice-a-day cancer pill. That approval marks another win on the targeted-cancer-drug front for Pfizer, which last year nabbed an FDA OK for its non-small-cell lung cancer treatment Xalkori for a subset of patients whose tumors express ALK mutations. Pfizer also markets two other drugs for advanced kidney cancer, Sutent and Torisel. Inlyta joins a crowded market: According to the FDA, there have now been 7 drugs for kidney cancer approved in the U.S. since the agency's nod for sorafenib in 2005. Story | More